What is the efficacy and safety of febuxostat in lowering hyperuricemia in black patients?

Updated: Jan 26, 2021
  • Author: Bruce M Rothschild, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print
Answer

In African-American subjects, the primary endpoint was reached in 47% on febuxostat 40 mg/day, 68% on febuxostat 80 mg/day, and 43% on allopurinol. Similar rates were seen in subjects with renal impairment. [171] Adverse event rates in both subgroups were comparable with those in the overall trial.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!